Femtech investment used to sound like a buzzword I would hear at conferences and forget by dinner. Then I read the market forecasts, and the numbers rearranged my thinking. Women’s health technology now covers fertility, menopause, chronic disease, and mental health. Because the industry finally matches the size of its market, it looks less like a trend and more like a decades-long shift.
I am writing this as an investor, not a medical advisor. I have no stock picks in mind, and you should not trust anyone who hands you one. Instead, I want to show you why the sector is growing, where the money is flowing, and how a woman over 35 can participate without gambling.
Femtech Investment: From Niche to Megatrend
A decade ago, women’s health technology was a small corner of the startup world. However, the market has moved since then. Global Market Insights values the femtech market at 66.2 billion dollars in 2025 and projects 255.5 billion by 2035, a compound growth rate of nearly 15 percent a year . Numbers like these are why the word megatrend appears so often now.
For context, a 15 percent annual growth rate roughly doubles the market every five years. Few industries maintain that pace for a decade. Because the customer base is half the human race and the products finally exist, the math has room to run. This is the part of investing I actually enjoy: when the numbers and the mission point the same way.
The Numbers Behind the Theme
The venture capital numbers are just as loud. Silicon Valley Bank reports that 2 billion dollars flowed into female-focused care companies in the United States and Europe during 2025 alone, bringing the total to 6.2 billion since 2019 . Meanwhile, more than 210 new startups entered the space in that same period.
The detail that caught my eye involves artificial intelligence. AI-enabled companies in this space fetch about three times the sector median valuation, according to the same report. When technology compounds with biology, the winners tend to scale quickly. This is exactly the pattern I look for when I study any long-term theme.
What impresses me most is not the headline number but the breadth. Investors fund fertility clinics, menopause apps, pelvic health devices, and maternal care platforms. When a sector attracts money across that many categories, it signals a structural shift rather than a single product fad. The pattern repeats in every major health technology wave.
Where the Innovation Is Happening
The innovation is happening where the unmet needs are oldest. Fertility tracking has grown into full reproductive health platforms. Indeed, menopause care, ignored for decades, now has dedicated clinics and digital products. Chronic conditions like endometriosis and PCOS finally have research money behind them. Each of these categories is a market with its own engine.
What makes this different from past health fads is the business model. Software subscriptions, employer benefits, and insurance partnerships create recurring revenue, the kind investors can count. Because the revenue repeats, the companies can plan years ahead. That is the difference between a fad and a market.
How a 35+ Woman Can Play It (Without Picking Stocks)
Here is the practical part. You do not need to pick a single company, and you should not. Theme investing works better through diversified funds and ETFs that track healthcare and innovation baskets. Similarly, the same logic applies as with any new sector: small allocation, long horizon, and rebalancing discipline.
If you already understand why women need to invest differently, you know the playbook . Longer horizons suit women naturally, and theme investing rewards exactly that. So my personal rule is boring: no more than five percent of my portfolio in themes like this, and I review it once a year. I have also written before about how femtech 2.0 is reshaping healthcare .
One practical note about allocations. Before adding any theme, the basics must be in place: an emergency fund, low-fee index funds, and a clear time horizon. Theme exposure is the seasoning, not the meal. Because the fundamentals already carry your plan, the theme adds flavor without changing the recipe.
Risks and Realism
No theme grows in a straight line. Regulation can slow new products, clinical trials can fail, and valuations can overshoot. Because healthcare sits under heavy regulation, timelines run longer than the tech sector average. Anyone who promises quick wins in femtech is selling something.
I also watch for a subtler risk: women’s health funding follows economic cycles, and this sector had a slow stretch in 2022 like every growth area did. However, the long-term demographics do not change with quarterly headlines. The market size forecasts rest on population math, and population math is stubbornly reliable.
The Throughline: Health and Wealth
The macro backdrop ties everything together. Women spend 25 percent more of their lives in poor health, and closing that gap is worth more than a trillion dollars a year by 2040 ., according to the World Economic Forum. Femtech sits exactly at the intersection of that problem and its solutions. When the problem is this large, the market tends to follow.
I started this piece with a confession about buzzwords, so let me end with a conviction. Femtech investment is not a short-term story for me. It is a long-term theme with real products, real revenue, and real patients behind it. As a woman over 35, I am not just an outside observer of this trend. I am one of its customers, and that is a position no other investor can copy.
Written by Maya Torres for March-8.